Dataset Information

Clinical impact of PET/MRI in oligometastatic colorectal cancer.

ABSTRACT:

Background

Oligometastatic colorectal cancer (CRC) is potentially curable and demands individualised strategies.

Methods

This single-centre retrospective study investigated if positron emission tomography (PET)/magnetic resonance imaging (MR) had a clinical impact on oligometastatic CRC relative to the standard of care imaging (SCI). Adult patients with oligometastatic CRC on SCI who also underwent PET/MR between 3/2016 and 3/2019 were included. The exclusion criterion was lack of confirmatory standard of reference, either surgical pathology, intraoperative gross confirmation or imaging follow-up. SCI consisted of contrast-enhanced (CE) computed tomography (CT) of the chest/abdomen/pelvis, abdominal/pelvic CE-MR, and/or CE whole-body PET/CT with diagnostic quality (i.e. standard radiation dose) CT. Follow-up was evaluated until 3/2020.

Results

Thirty-one patients constituted the cohort, 16 (52%) male, median patient age was 53 years (interquartile range: 49-65 years). PET/MR and SCI results were divergent in 19% (95% CI 9-37%) of the cases, with PET/MR leading to management changes in all of them. The diagnostic accuracy of PET/MR was 90 ± 5%, versus 71 ± 8% for SCI. In a pairwise analysis, PET/MR outperformed SCI when compared to the reference standard (p = 0.0412).

Conclusions

These findings suggest the potential usefulness of PET/MR in the management of oligometastatic CRC.

SUBMITTER: Furtado FS

PROVIDER: S-EPMC8476553 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Clinical impact of PET/MRI in oligometastatic colorectal cancer.

Furtado Felipe S FS Suarez-Weiss Krista E KE Vangel Mark M Clark Jeffrey W JW Cusack James C JC Hong Theodore T Blaszkowsky Lawrence L Wo Jennifer J Striar Robin R Umutlu Lale L Daldrup-Link Heike E HE Groshar David D Rocco Ricciardi R Bordeianou Liliana L Anderson Mark A MA Mojtahed Amirkasra A Qadan Motaz M Ferrone Cristina C Catalano Onofrio A OA

British journal of cancer 20210719 7

<h4>Background</h4>Oligometastatic colorectal cancer (CRC) is potentially curable and demands individualised strategies.<h4>Methods</h4>This single-centre retrospective study investigated if positron emission tomography (PET)/magnetic resonance imaging (MR) had a clinical impact on oligometastatic CRC relative to the standard of care imaging (SCI). Adult patients with oligometastatic CRC on SCI who also underwent PET/MR between 3/2016 and 3/2019 were included. The exclusion criterion was lack of ...[more]

PMID: 34282295

Similar Datasets

Project description:BackgroundProstate-specific membrane antigen (PSMA) positron emission tomography (PET) can change management in a large fraction of patients with biochemically recurrent prostate cancer (BCR).PurposeTo investigate the added value of PET to MRI and CT for this patient group, and to explore whether the choice of the PET paired modality (PET/MRI vs. PET/CT) impacts detection rates and clinical management.Study typeRetrospective.Subjects41 patients with BCR (median age [range]: 68 [55-78]).Field strength/sequence3T, including T1-weighted gradient echo (GRE), T2-weighted turbo spin echo (TSE) and dynamic contrast-enhanced GRE sequences, diffusion-weighted echo-planar imaging, and a T1-weighted TSE spine sequence. In addition to MRI, [18F]PSMA-1007 PET and low-dose CT were acquired on the same day.AssessmentImages were reported using a five-point Likert scale by two teams each consisting of a radiologist and a nuclear medicine physician. The radiologist performed a reading using CT and MRI data and a joint reading between radiologist and nuclear medicine physician was performed using MRI, CT, and PET from either PET/MRI or PET/CT. Findings were presented to an oncologist to create intended treatment plans. Intrareader and interreader agreement analysis was performed.Statistical testsMcNemar test, Cohen's κ, and intraclass correlation coefficients. A P-value <0.05 was considered significant.Results7 patients had positive findings on MRI and CT, 22 patients on joint reading with PET/CT, and 18 patients joint reading with PET/MRI. For overall positivity, interreader agreement was poor for MR and CT (κ = 0.36) and almost perfect with addition of PET (PET/CT κ = 0.85, PET/MRI κ = 0.85). The addition of PET from PET/CT and PET/MRI changed intended treatment in 20 and 18 patients, respectively. Between joint readings, intended treatment was different for eight patients.Data conclusionThe addition of [18F]PSMA-1007 PET/MRI or PET/CT to MRI and CT may increase detection rates, could reduce interreader variability, and may change intended treatment in half of patients with BCR.Level of evidence3 TECHNICAL EFFICACY: Stage 3.

Dataset Information

Clinical impact of PET/MRI in oligometastatic colorectal cancer.

Background

Methods

Results

Conclusions

Publications

Clinical impact of PET/MRI in oligometastatic colorectal cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets